* Veracyte Inc VCYT.OQ VCYT.O is expected to show a rise
in
quarterly revenue when it reports results on May 7 for the
period ending March 31 2024
* The South San Francisco California-based company is
expected to
report a 13.3% increase in revenue to $93.37 million from $82.42
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Veracyte Inc is for a
loss
of 18 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Veracyte
Inc is
$32.50, above its last closing price of $20.35.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.08 -0.09 -0.39 Missed -317.9
Sep. 30 2023 -0.14 -0.15 -0.41 Missed -179.6
Jan. 1 0001 -0.15 -0.15 -0.12 Beat 21.4
Mar. 31 2023 -0.15 -0.13 -0.11 Beat 17.8
Dec. -0.15 -0.15 -0.05 Beat 67
31 2022
Sep. 30 2022 -0.24 -0.25 -0.12 Beat 51.7
Jun. 30 2022 -0.22 -0.22 -0.13 Beat 40.5
Mar. 31 2022 -0.24 -0.24 -0.20 Beat 15.9
This summary was machine generated May 4 at 01:34 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)